Brief: Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
03/09/2024 12:06
Sept 3 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES RECEIVES $13 MILLION IN PROCEEDS
FROM
IMUGENE CONVERTIBLE NOTE MATURITY AS PART OF THE AUGUST 2023
AZER-CEL DEAL
* PRECISION BIOSCIENCES INC: PAYMENT INCLUDES $9.75 MILLION
CASH
AND $3.25 MILLION IN IMUGENE LIMITED ORDINARY SHARES
* PRECISION BIOSCIENCES INC: EXPECTED CASH RUNWAY INTO
SECOND HALF
OF 2026
Source text for Eikon: ID:nBw8d6r8ma
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing